Patents by Inventor Athanasios Dousis
Athanasios Dousis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240102066Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: ApplicationFiled: August 11, 2023Publication date: March 28, 2024Applicant: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Patent number: 11939601Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.Type: GrantFiled: November 21, 2018Date of Patent: March 26, 2024Assignee: ModernaTX, Inc.Inventors: Raj Rajendran, Patrick Finn, Paolo G. V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
-
Patent number: 11767548Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: GrantFiled: June 17, 2021Date of Patent: September 26, 2023Assignee: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Publication number: 20230235298Abstract: Variant phenylalanine hydroxylase polypeptides having substitutions at selected amino acid residues are disclosed. Also disclosed are methods of using variant phenylalanine hydroxylase polypeptides, or polynucleotides encoding variant phenylalanine hydroxylase polypeptides, to treat disorders such as phenylketonuria.Type: ApplicationFiled: June 1, 2021Publication date: July 27, 2023Inventors: Lisa M. Rice, Patrick Finn, Athanasios Dousis
-
Publication number: 20230104080Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.Type: ApplicationFiled: August 1, 2022Publication date: April 6, 2023Applicant: ModernaTX, Inc.Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
-
Publication number: 20230009009Abstract: This disclosure relates to mRNA therapy for the treatment of glycogen storage disease type 1a, (GSD-Ia), and related symptoms such as hypoglycemia. mRNAs for use in the invention, when administered in vivo, encode human glucose-6-phosphatase (G6Pase or G6PC), and functional fragments and variants thereof. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of G6PC expression and/or activity in subjects. mRNA therapies of the invention further increase the glucose production, and reduce the abnormal accumulation of glycogen and/or glucose-6-phosphate associated with GSD-Ia.Type: ApplicationFiled: September 12, 2019Publication date: January 12, 2023Inventors: Paolo G. V. Martini, Athanasios Dousis, Vladimir Presnyak, Jingsong Cao
-
Patent number: 11485960Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.Type: GrantFiled: May 20, 2021Date of Patent: November 1, 2022Assignee: ModernaTX, Inc.Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
-
Publication number: 20210395792Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: ApplicationFiled: June 17, 2021Publication date: December 23, 2021Applicant: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Publication number: 20210309976Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.Type: ApplicationFiled: May 20, 2021Publication date: October 7, 2021Applicant: ModernaTX, Inc.Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith
-
Patent number: 11066686Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: GrantFiled: October 18, 2019Date of Patent: July 20, 2021Assignee: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Publication number: 20210217484Abstract: Techniques for manufacturing a variant of a target protein. The techniques may include accessing a latent variable statistical model (LVSM) configured to generate output indicating one or more biological sequences corresponding to one or more variants of the target protein and using the LVSM to generate a first output indicating a first biological sequence associated with a first variant of the target protein. The techniques further include manufacturing, using the first biological sequence, a first biological molecule to produce the first variant of the target protein.Type: ApplicationFiled: January 8, 2021Publication date: July 15, 2021Applicant: ModernaTX, Inc.Inventors: Andrew Giessel, Athanasios Dousis, Iain McFadyen
-
Publication number: 20210040456Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.Type: ApplicationFiled: November 21, 2018Publication date: February 11, 2021Applicant: ModernaTX, Inc.Inventors: Raj Rajendran, Patrick Finn, Paolo G.V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
-
Publication number: 20200354429Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.Type: ApplicationFiled: July 30, 2020Publication date: November 12, 2020Applicant: MODERNATX, INC.Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
-
Patent number: 10730924Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.Type: GrantFiled: July 2, 2018Date of Patent: August 4, 2020Assignee: ModernaTX, Inc.Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
-
Publication number: 20200131550Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: ApplicationFiled: October 18, 2019Publication date: April 30, 2020Applicant: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Patent number: 10526629Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: GrantFiled: June 5, 2019Date of Patent: January 7, 2020Assignee: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Patent number: 10465190Abstract: The present disclosure provides, in some aspects, in vitro transcription systems (including, for example, nucleic acid constructs and polymerases), the use of which increases transcription efficiency while reducing the amount of truncated single-stranded ribonucleic acid transcript produced during an in vitro transcription reaction.Type: GrantFiled: December 21, 2016Date of Patent: November 5, 2019Assignee: ModernaTX, Inc.Inventors: Jesse Chen, Athanasios Dousis
-
Publication number: 20190309337Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: ApplicationFiled: June 5, 2019Publication date: October 10, 2019Applicant: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Publication number: 20180371047Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.Type: ApplicationFiled: July 2, 2018Publication date: December 27, 2018Applicant: ModernaTX, Inc.Inventors: Barry Ticho, Nadege Briancon-Eris, Zhinan Xia, Athanasios Dousis, Seymour de Picciotto, Vladimir Presnyak, Stephen Hoge, Iain Mcfadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe